A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This is the first-in-human study of the safety of increasing dose levels of AEB1102 in
patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in blood,
the effects of AEB1102 on blood amino acid levels and tumor growth.